📣 FDA Approves Sofdra™ topical gel #Botanix is very pleased to announce the US FDA approval of Sofdra™ (sofpironium) topical gel, 12.45%. Sofdra is a prescription medicine used to treat primary axillary hyperhidrosis (excessive underarm sweating) in adults and children 9 years and older. View ASX release 👉 https://lnkd.in/gzHx8Q9k $BOT #ASX #dermatology #pharmaceuticals #pharma #biotech #innovation #hyperhidrosis #launch
Although this was a departure from the original strategy, this is GREAT news.... now looking forward to the progress in the remaining products in BOT's cache.
Never a doubt 😃
Congratulations to Botanix Pharmaceuticals on the FDA approval of Sofdra™! 🎉 This is a significant milestone for primary axillary hyperhidrosis treatment. Looking forward to seeing its impact on patients' lives.
Great news for patients!
Brilliant!
Congratulations my friend
Congratulations to the whole Botanix team!
Congratulations to you and the entire Botanix team Howie!
Huge news! Transformational!
Executive | Pharmaceutical Consulting | Product Launch | Analytics | Market Research | Market Access Strategy
1moGreat news for a great team! Viking Healthcare Solutions is grateful to be working with the Botanix team to launch Sofdra in the market for patients in need.